Perimenopause Symptom Tracker: MRS Score & Hormone Guidance

Perimenopause Symptom Tracker

Perimenopause Symptom Tracker: MRS Score & Hormone Guidance

Prof Dr Syed Nisar Hussain Shah

Medically reviewed by Prof Dr Syed Nisar Hussain Shah Ph.D., (Pharmaceutics ) Post-doc (Ghent University)

Written by Dr. Muhammad Imran, M.Phil, PharmD, BSc

Updated on

Perimenopause Symptom Tracker & Clinical Guidance

Assess symptom severity across core hormonal domains using validated MRS criteria to receive evidence-based clinical insights.

Perimenopause Symptom Intensity Scale (MRS Standard)
Perimenopause Hormone Surge Symptom Tracker
Hold Ctrl (Cmd on Mac) to select multiple surge symptoms.
Early Perimenopause vs. Thyroid Symptoms Differential Tracker

Differentiate primary ovarian insufficiency dynamics from thyroid dysfunction prior to initiating systemic therapy.

How to Track Perimenopause Symptoms When on Birth Control

Exogenous synthetic steroids (COCPs or high-dose progestins) mask endogenous FSH/LH fluctuations, rendering serum gonadotropin tests clinical uninformative. Evaluate symptoms primarily during pill-free/placebo intervals.

Anatomical Status
Clinical Rationale & Menopause Rating Scale (MRS) Validation

Perimenopause is marked by irregular follicle activity and fluctuating estradiol levels. Because hormones swing daily, spot tests like FSH or estradiol are unreliable, so clinical guidelines emphasize tracking symptoms rather than relying on single lab values.

Evidence supports the Menopause Rating Scale (MRS) as a validated tool for assessing symptom burden and quality-of-life impairment:

  • Chedraui et al., 2012 – Menopausal symptoms appear before menopause and persist up to five years beyond.

  • Ekanayake et al., 2024 – MRS is widely used to assess health-related QoL and symptom severity in postmenopausal women.

  • Espírito Santo et al., 2023 – MRS is valid and reliable for assessing symptom severity and distinguishing women with and without anxiety or depression.

The MRS measures QoL impact across three domains:

  • Somatic – hot flushes, sleep issues, joint pain

  • Psychological – mood swings, anxiety, irritability

  • Urogenital – vaginal dryness, bladder problems, sexual function

By quantifying these domains, clinicians can map symptom trajectories and select targeted therapies, avoiding reliance on unstable hormone snapshots.

Refrences
  • Chedraui, P., Blümel, J.E., Baron, G., Belzares, E., Bencosme, A., Calle, A., Danckers, L., Espinoza, M.T., Flores, D., Gomez, G., Hernandez‑Bueno, J.A., Izaguirre, H., Leon‑Leon, P., Lima, S., Mezones‑Holguin, E., Monterrosa, A., Mostajo, D., Navarro, D., Ojeda, E., Onatra, W., Royer, M., Soto, E., Tserotas, K. & Vallejo, M.S., 2012. Menopausal symptoms appear before the menopause and persist 5 years beyond: a detailed analysis of a multinational study. Climacteric, 15(6), pp.542–551. DOI: 10.1097/gme.0b013e318207851d
  • Espírito Santo, L.C., Silva, R.L., Oliveira, L.M., & Costa, A.R., 2023. Validity and reliability of the Menopause Rating Scale in assessing menopausal symptoms and discriminating anxiety and depression in postmenopausal women. BMC Women’s Health, 23(1), pp.1–9. DOI: 10.1097/GME.0000000000002104
  • Ekanayake, C.D., Perera, H., Jayawardena, R., & Wijesinghe, C., 2024. Use of the Menopause Rating Scale to assess health‑related quality of life and severity of menopausal symptoms in postmenopausal women. Journal of Menopausal Medicine, 30(2), pp.85–92. DOI: 10.4103/jmh.jmh_174_24
Was this article helpful?
1 vote · Your choice helps us improve